Rift Genomics · MRD monitoring solution
Track every clone,at every timepoint.
NGS immunosequencing kit and clone-tracking software for measurable residual disease in multiple myeloma, B-ALL and T-ALL.
RUOResearch Use Only
- BCR + TCR
- Myeloma, B-ALL and T-ALL on two panels, one workflow
- Kit + software
- Library-prep kit and clone tracking, supplied together
- In-house
- Bring sequencing and interpretation together in your laboratory
- Every timepoint
- From diagnosis through maintenance and after CAR-T
Clinical need
MRD is now part of standard care.
The latest myeloma and ALL guidelines make MRD a routine, repeated measurement. Laboratories need to run it in-house, at depth, at every timepoint.
Multiple myeloma · NCCN, September 2026
Multiple myeloma
- Dedicated MRD testing page in the guideline
- Bone marrow MRD by NGS or flow cytometry
- Sensitivity of 10⁻⁵ minimum, 10⁻⁶ preferred
- Test after treatment, yearly during maintenance and after CAR-T
- New IMS/IMWG cure definition: at least four negative MRD tests at 10⁻⁶ over five years
Acute lymphoblastic leukaemia · NCCN
Acute lymphoblastic leukaemia
- MRD at end of induction and at later timepoints
- Sensitivity of at least 10⁻⁴; NGS can reach 10⁻⁶
- Both B-ALL and T-ALL must be covered
What the sensitivity levels mean
Guideline points summarised from NCCN Guidelines for Multiple Myeloma (September 2026) and Acute Lymphoblastic Leukaemia, and the IMS/IMWG cure definition (September 2026). Always refer to the current guideline version.
Coverage
| Disease | Cell of origin | Receptor genes tracked | Rift panel |
|---|---|---|---|
| Multiple myeloma | B cell | IGH, IGK, IGL | BCR panel |
| B-ALL | B cell | IGH, IGK, IGL | BCR panel |
| T-ALL | T cell | TCR beta, gamma, alpha, delta | TCR panel |
Why NGS-based MRD
One panel for every patient. A sequence-level answer.
Each patient’s clones are identified from the diagnostic sample, then followed by their exact CDR3 sequence at every later timepoint.
No patient-specific assay design
The same panel runs for every patient. Each patient’s clones are identified from the diagnostic sample.
Several clones at once
Heavy and light chains are tracked together, so clonal evolution is less likely to be missed.
Sequence-level result
Each clone is identified by its exact CDR3 sequence, giving a digital, reproducible readout.
The kit
Immunosequencing built for rare clones.
Two targeted NGS panels, one for B-cell receptors and one for T-cell receptors, share a single adapter-anchored targeted PCR workflow.
One primer sits in the conserved constant region; the other end is the ligated adapter. No primer has to bind the hypervariable V(D)J sequence.
Reads through hypervariable regions
Primers bind the conserved constant region, so V(D)J diversity and variable fragment lengths do not cause drop-outs.
Molecular barcodes
A unique tag on every input molecule lets the software collapse PCR copies and discard sequencing errors.
Nested PCR
A second gene-specific primer adds specificity, so low-level clones stand out from background.
From sample to MRD status
- SampleBone marrow, blood or tissue
- RNAExtract total RNA
- LibraryRift kit1.5 days
- SequenceIllumina
- TrackRift MRD software
- ReportMRD status per timepoint
| Rift BCR panel | Rift TCR panel | |
|---|---|---|
| Targets | IGH heavy chain plus kappa and lambda light chains, with isotype calling | TCR beta, gamma, alpha and delta chains |
| Applications | MRD tracking, clonality, hypermutation status, repertoire studies | MRD tracking, clonality, repertoire and T-cell infiltration studies |
| Input | 20 ng – 6 µg total RNA | 20 ng – 2 µg total RNA |
| Sample types | Bone marrow, blood, PBMC, sorted B cells, FFPE, fresh frozen | Blood, PBMC, sorted T cells, FFPE, fresh frozen |
| Sequencing | Illumina · 250K – 10M reads per sample | Illumina · 250K – 10M reads per sample |
| Hands-on time | 3.5 hours | 3.5 hours |
| Library prep | 1.5 days | 1.5 days |
| Format | Freeze-dried reagents, one tube per reaction | Freeze-dried reagents, one tube per reaction |
How much RNA and how many reads you need depends on the sample and on the depth of MRD testing required.
The software
From reads to MRD status, per patient.
Rift MRD software links every sample to its patient, finds the index clones at diagnosis and tracks them at every later timepoint.
Index clone frequency over time
Tracked clones
| Clone | Locus | CDR3 | Dx | Latest |
|---|---|---|---|---|
| C1 | IGH | CARDGYSSGWYFDYW | 41.2% | neg. |
| C2 | IGK | CQQYNSYPLTF | 38.7% | neg. |
| C3 | IGH | CAKDRGYCSGGSCYW | 0.9% | neg. |
| C4 | IGL | CQSYDSSLSGSVF | 0.3% | neg. |
Status at M1: MRD-negative · 4 index clones tracked
Explore example data.
Index clone detection
Identifies each patient’s malignant clonotypes from the diagnostic sample.
Longitudinal tracking
Follows the same clones across every follow-up sample, from induction to maintenance.
Error-corrected counts
Uses molecular barcodes to remove PCR duplicates and sequencing errors before counting.
MRD timeline
Shows clone frequency and MRD status at each timepoint, against guideline thresholds.
Ready-to-sign reports
Generates a per-patient MRD report for review and sign-off by your team.
Local or on-premise
Runs on your own servers, so patient data stays inside your institution.
One supplier, from kit to report
Everything you need to get running.
- Kit supply and logistics
- Software installation and training
- Implementation and validation support
- Ongoing scientific and technical support
RUOFor Research Use Only. Not for use in diagnostic procedures.
Bring MRD testing
in-house.
See the kit and software in a demonstration, or talk to us about implementation and validation.